Your Biotech May Be a Buyout Target -- But Don’t Bet On It

The smaller biotech jumped as much as 15.8% on the report from Bloomberg and hype from other news agencies.

This is not news. Juno doesn’t deserve an elevated valuation based on the quote. There are so many things wrong with this situation.

Hey, check out all the research scientist jobs. Post your resume today!

MORE ON THIS TOPIC